183 related articles for article (PubMed ID: 27068849)
1. Factors associated with non-adherence and misuse of opioid maintenance treatment medications and intoxicating drugs among Finnish maintenance treatment patients.
Launonen E; Wallace I; Kotovirta E; Alho H; Simojoki K
Drug Alcohol Depend; 2016 May; 162():227-35. PubMed ID: 27068849
[TBL] [Abstract][Full Text] [Related]
2. Diversion of opioid maintenance treatment medications and predictors for diversion among Finnish maintenance treatment patients.
Launonen E; Alho H; Kotovirta E; Wallace I; Simojoki K
Int J Drug Policy; 2015 Sep; 26(9):875-82. PubMed ID: 25934054
[TBL] [Abstract][Full Text] [Related]
3. Intravenous Misuse of Methadone, Buprenorphine and Buprenorphine-Naloxone in Patients Under Opioid Maintenance Treatment: A Cross-Sectional Multicentre Study.
Lugoboni F; Zamboni L; Cibin M; Tamburin S;
Eur Addict Res; 2019; 25(1):10-19. PubMed ID: 30625491
[TBL] [Abstract][Full Text] [Related]
4. Dissatisfaction with opioid maintenance treatment partly explains reported side effects of medications.
Muller AE; Bjørnestad R; Clausen T
Drug Alcohol Depend; 2018 Jun; 187():22-28. PubMed ID: 29626742
[TBL] [Abstract][Full Text] [Related]
5. Intravenous misuse of buprenorphine: characteristics and extent among patients undergoing drug maintenance therapy.
Moratti E; Kashanpour H; Lombardelli T; Maisto M
Clin Drug Investig; 2010; 30 Suppl 1():3-11. PubMed ID: 20450240
[TBL] [Abstract][Full Text] [Related]
6. Willingness to receive intravenous buprenorphine treatment in opioid-dependent people refractory to oral opioid maintenance treatment: results from a community-based survey in France.
Roux P; Rojas Castro D; Ndiaye K; Briand Madrid L; Laporte V; Mora M; Maradan G; Morel S; Spire B; Carrieri P
Subst Abuse Treat Prev Policy; 2017 Nov; 12(1):46. PubMed ID: 29096661
[TBL] [Abstract][Full Text] [Related]
7. Polydrug abuse among opioid maintenance treatment patients is related to inadequate dose of maintenance treatment medicine.
Heikman PK; Muhonen LH; Ojanperä IA
BMC Psychiatry; 2017 Jul; 17(1):245. PubMed ID: 28683783
[TBL] [Abstract][Full Text] [Related]
8. Are patients' pejorative representations of buprenorphine associated with their level of addiction and of misuse?
Vanderkam P; Gagey S; Ingrand P; Perault-Pochat MC; Brabant Y; Blanchard C; Tudrej B; Messaadi N; Binder P
Drug Alcohol Depend; 2018 Jul; 188():10-15. PubMed ID: 29727755
[TBL] [Abstract][Full Text] [Related]
9. Opioid maintenance therapy in Switzerland: an overview of the Swiss IMPROVE study.
Besson J; Beck T; Wiesbeck G; Hämmig R; Kuntz A; Abid S; Stohler R
Swiss Med Wkly; 2014; 144():w13933. PubMed ID: 24706398
[TBL] [Abstract][Full Text] [Related]
10. [Management of opioid maintenance treatments when analgesic treatments are required].
Laprevote V; Geoffroy PA; Rolland B; Leheup BF; Di Patrizio P; Cottencin O; Schwan R
Presse Med; 2013; 42(7-8):1085-90. PubMed ID: 23518339
[TBL] [Abstract][Full Text] [Related]
11. Why do patients stay in opioid maintenance treatment?
Gutwinski S; Bald LK; Gallinat J; Heinz A; Bermpohl F
Subst Use Misuse; 2014 May; 49(6):694-9. PubMed ID: 24328842
[TBL] [Abstract][Full Text] [Related]
12. Association between Adult Attention Deficit/Hyperactivity Disorder and Intravenous Misuse of Opioid and Benzodiazepine in Patients under Opioid Maintenance Treatment: A Cross-Sectional Multicentre Study.
Lugoboni F; Zamboni L; Mantovani E; Cibin M; Tamburin S;
Eur Addict Res; 2020; 26(4-5):263-273. PubMed ID: 31995807
[TBL] [Abstract][Full Text] [Related]
13. Patterns of physician prescribing for opioid maintenance treatment in Ontario, Canada in 2014.
Guan Q; Khuu W; Spithoff S; Kiran T; Kahan M; Tadrous M; Martins D; Leece P; Gomes T
Drug Alcohol Depend; 2017 Aug; 177():315-321. PubMed ID: 28733101
[TBL] [Abstract][Full Text] [Related]
14. A latent class analysis of self-reported clinical indicators of psychosocial stability and adherence among opioid substitution therapy patients: do stable patients receive more unsupervised doses?
Larance B; Carragher N; Mattick RP; Lintzeris N; Ali R; Degenhardt L
Drug Alcohol Depend; 2014 Sep; 142():46-55. PubMed ID: 25015687
[TBL] [Abstract][Full Text] [Related]
15. Treatment retention, drug use and social functioning outcomes in those receiving 3 months versus 1 month of supervised opioid maintenance treatment. Results from the Super C randomized controlled trial.
Holland R; Maskrey V; Swift L; Notley C; Robinson A; Nagar J; Gale T; Kouimtsidis C
Addiction; 2014 Apr; 109(4):596-607. PubMed ID: 24304349
[TBL] [Abstract][Full Text] [Related]
16. Is there enough naloxone to deter the diversion? Effect of concurrent administration of intravenous naloxone on opioid agonist effects of intravenous buprenorphine: A randomised, double-blind, within-subject, crossover study among opioid-dependent subjects.
Dhagudu NK; Ambekar A; Agrawal A; Rao R; Mishra AK; Jain R; Singh S
Drug Alcohol Rev; 2020 Jul; 39(5):595-603. PubMed ID: 32162420
[TBL] [Abstract][Full Text] [Related]
17. Understanding abuse of buprenorphine/naloxone film versus tablet products using data from ASI-MV® substance use disorder treatment centers and RADARS® System Poison Centers.
Butler SF; Black RA; Severtson SG; Dart RC; Green JL
J Subst Abuse Treat; 2018 Jan; 84():42-49. PubMed ID: 29195592
[TBL] [Abstract][Full Text] [Related]
18. Prescribing of drugs for attention-deficit hyperactivity disorder in opioid maintenance treatment patients in Norway.
Karlstad Ø; Furu K; Skurtveit S; Selmer R
Eur Addict Res; 2014; 20(2):59-65. PubMed ID: 24080771
[TBL] [Abstract][Full Text] [Related]
19. Neonatal outcomes following in utero exposure to methadone or buprenorphine: a National Cohort Study of opioid-agonist treatment of Pregnant Women in Norway from 1996 to 2009.
Welle-Strand GK; Skurtveit S; Jones HE; Waal H; Bakstad B; Bjarkø L; Ravndal E
Drug Alcohol Depend; 2013 Jan; 127(1-3):200-6. PubMed ID: 22841456
[TBL] [Abstract][Full Text] [Related]
20. New psychoactive substances as part of polydrug abuse within opioid maintenance treatment revealed by comprehensive high-resolution mass spectrometric urine drug screening.
Heikman P; Sundström M; Pelander A; Ojanperä I
Hum Psychopharmacol; 2016 Jan; 31(1):44-52. PubMed ID: 26763789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
